Solicitation of Nominations for Organizations To Serve as Non-Voting Liaison Representatives to the Chronic Fatigue Syndrome Advisory Committee (CFSAC), 5454-5456 [2013-01456]
Download as PDF
<![CDATA[
5454
Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat (MVCB), 1275
First Street NE., Washington, DC 20417,
telephone (202) 501–4755. Please cite
OMB Control No. 9000–0083,
Qualification Requirements, in all
correspondences.
Dated: January 18, 2013.
William Clark,
Acting Director, Federal Acquisition Policy
Division, Office of Governmentwide
Acquisition Policy, Office of Acquisition
Policy, Office of Governmentwide Policy.
[FR Doc. 2013–01557 Filed 1–24–13; 8:45 am]
BILLING CODE 6820–EP–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Rao M. Adibhatla, Ph.D., University of
Wisconsin: Based on the report of an
investigation conducted by the
University of Wisconsin (UW) and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Rao M. Adibhatla, Assistant Professor,
Department of Neurological Surgery,
UW, engaged in research misconduct by
falsifying results in two publications
supported by National Institute of
Neurological Diseases and Stroke
(NINDS), National Institutes of Health
(NIH), grant R01 NS042008 and in three
unfunded applications that Dr.
Adibhatla submitted to NINDS, NIH, as
R01 NS042008–05, –05A1, and –05A2.
The questioned papers are:
mstockstill on DSK4VPTVN1PROD with
SUMMARY:
1. Adibhatla, R.M., Hatcher, J.F., Larsen E.C.
et al. ‘‘CDP-choline Significantly Restores
Phoshatidylcholine Levels by Differentially
Affecting Phospholipase A2 and
CTP:Phosphocholine Cytidylyltransferase
after Stroke.’’ J. Biol. Chem. 281:6718–
6725, 2006 (hereafter referred to as the
‘‘JBC paper’’), as the sPLA2-IIA, CCTa, and
PLD2 data in Figures 1B, 2A, and 3A,
respectively
2. Adibhatla, R.M., & Hatcher, J.F. ‘‘Secretory
phospholipase A2 IIA is Up-regulated by
TNF-a and IL-1a/b after Transient Focal
Cerebral Ischemia in Rat.’’ Brain Research
1134:199–205, 2007 (hereafter referred to
as the ‘‘Brain Research paper’’), as the
sPLA2-IIA data in Figures 2A and 2C.
VerDate Mar<15>2010
18:39 Jan 24, 2013
Jkt 229001
ORI found that Respondent
committed research misconduct by
falsifying Western blot images as well as
quantitative and statistical data obtained
from purported scans of the films. The
research studied the effect of cerebral
ischemia on phospholipid homeostasis
in an experimental animal model (SHR
rat) of stroke during the course of
reperfusion of the ischemic cortex. The
falsified Western blot images and
derivative quantitative data describe
changes in levels of sPLA2-IIAA, CCTa,
and of PLD2 during reperfusion in the
ischemic cortex.
Specifically, the Respondent:
• Falsified the Western blot data
demonstrating sPLA2 expression in a
time course after ischemia in Figure 1B
of the JBC paper and Figure 2A and 2C
of the Brain Research paper by
rearranging the bands such that the
labels do not accurately portray what is
in the lanes. He perpetuated the
falsification by presenting the
quantification of the single falsified
Western blot in a bar graph as the
average of five (5) replicate Western
blots. The result in the paper cannot be
substantiated by the actual experiments.
• Falsified the Western blot data
demonstrating CCTa expression in a
time course assay after ischemia in
Figure 2A of the JBC paper by
rearranging the bands such that the
labels do not accurately portray what is
in the lanes. He perpetuated the
falsification by presenting the
quantification of the single falsified
Western blot in a bar graph as the
average of four (4) replicate Western
blots and the six (6) hour time point was
further falsified to make the results look
better. The result in the paper cannot be
substantiated by the actual experiments.
• Falsified the quantification of a
Western blot demonstrating PLD2
expression in a time course after
ischemia in Figure 3A of the JBC paper
by claiming a bar graph quantifying a
single Western blot is the average of four
Western blots.
• Submitted the same falsified
Western blot images and bar graph data
in three unfunded grant applications:
NS042008–05, NS042008–05A1, and
NS042008–05A2. Specifically:
< the falsified sPLA2-IIA data were
submitted as Figures 3, 8, and 12 in the
respective NS042008–05, –05A1, and
–05A2 applications
< the falsified CCTa data appeared as
Figures 10, 15, and 16 in the respective
–05, –05A1, and –05A2 applications
< The falsified PLD2 bar graph data
and associated statistical claims
appeared as Figures 8 and 13 in the –05
and –05A1 applications respectively.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Dr. Adibhatla has entered into a
Voluntary Exclusion Agreement and has
voluntarily agreed:
(1) To exclude himself voluntarily for
a period of two (2) years from the
effective date of the Agreement from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
nonprocurement programs of the United
States pursuant to HHS’ Implementation
(2 CFR part 376 et seq.) of OMB
Guidelines to Agencies on
Governmentwide Debarment and
Suspension, 2 CFR Part 180 (collectively
the ‘‘Debarment Regulations’’);
(2) To exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of three (3)
years beginning on December 18, 2012;
and
(3) To request retraction of the
following papers:
• J. Biol. Chem. 281:6718–6725, 2006
• Brain Research 1134:199–205,
2007.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2013–01454 Filed 1–24–13; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation of Nominations for
Organizations To Serve as Non-Voting
Liaison Representatives to the Chronic
Fatigue Syndrome Advisory
Committee (CFSAC)
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
Authority: 42 U.S.C. 217a, section 222 of
the Public Health Service (PHS) Act, as
amended. The committee is governed by the
provisions of the Federal Advisory
Committee Act, as amended (5 U.S.C. App 2),
which sets forth standards for the formation
and use of advisory committees.
The Office of the Assistant
Secretary for Health (OASH), within the
Department of Health and Human
Services (HHS), is soliciting
nominations from qualified
organizations to be considered for nonvoting liaison representative positions
SUMMARY:
E:\FR\FM\25JAN1.SGM
25JAN1
Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices
on the Chronic Fatigue Syndrome
Advisory Committee (CFSAC). CFSAC
provides advice and recommendations
to the Secretary of HHS, through the
Assistant Secretary for Health (ASH), on
a broad range of issues and topics
related to myalgic encephalomyelitis/
chronic fatigue syndrome (ME/CFS).
The issues can include factors affecting
access and care for persons with ME/
CFS; the science and definition of ME/
CFS; and public health, clinical,
research, and educational issues related
to ME/CFS. These three non-voting
liaison representative positions will be
occupied by individuals who are
selected by their organizations to serve
as representatives of organizations
concerned with ME/CFS. Organizations
will be designated to occupy the
positions for a two-year term to
commence during the 2013 calendar
year. Nominations of qualified
organizations are being sought for these
three non-voting liaison representative
positions. The organizations chosen for
representation on CFSAC will be
selected by the Designated Federal
Officer (DFO) or designee during the
2013 calendar year. Details of
nomination requirements are provided
below.
Nominations must be received
no later than 5 p.m. EDT on February
22, 2013, at the address listed below.
ADDRESSES: All nominations should be
mailed or delivered to Nancy C. Lee,
M.D., Designated Federal Officer,
Chronic Fatigue Syndrome Advisory
Committee, Office on Women’s Health,
Department of Health and Human
Services, 200 Independence Ave. SW.,
Room 712E, Washington, DC 20201.
Nomination materials, including
attachments, may be submitted
electronically to cfsac@hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Nancy C. Lee, M.D., Designated Federal
Officer, Chronic Fatigue Syndrome
Advisory Committee, Office on
Women’s Health, Department of Health
and Human Services, 200 Independence
Ave. SW., Room 712E, Washington, DC
20201. Inquiries can be sent to
cfsac@hhs.gov.
DATES:
CFSAC
was established on September 5, 2002.
The purpose of the CFSAC is to provide
advice and recommendations to the
Secretary of HHS, through the ASH, on
issues related to ME/CFS. CFSAC
advises and makes recommendations on
a broad range of topics including: (1)
The current state of knowledge and
research; the relevant gaps in knowledge
and research about the epidemiology,
etiologies, biomarkers and risk factors
mstockstill on DSK4VPTVN1PROD with
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
18:39 Jan 24, 2013
Jkt 229001
relating to ME/CFS; and potential
opportunities in these areas; (2) impact
and implications of current and
proposed diagnostic and treatment
methods for ME/CFS; (3) development
and implementation of programs to
inform the public, health care
professionals, and the biomedical
research communities about ME/CFS
advances; and (4) strategies to improve
the quality of life of ME/CFS patients.
Management and support services for
Committee activities are provided by
staff from the HHS Office on Women’s
Health, within the OASH. The CFSAC
charter is available at https://www.hhs.
gov/advcomcfs/charter/.
CFSAC meetings are held not less
than two times per year. The CFSAC
membership consists of 11 voting
members, including the Chair. The
voting members are composed of seven
biomedical research scientists, and four
individuals with expertise in health
insurance, health care delivery, private
health care services, or representatives
of voluntary organizations concerned
with the problems of individuals with
ME/CFS. CFSAC also includes seven
non-voting ex officio member
representatives from the Agency for
Healthcare Research and Quality,
Centers for Disease Control and
Prevention, Centers for Medicare and
Medicaid Services, Food and Drug
Administration, Health Resources and
Services Administration, National
Institutes of Health, and Social Security
Administration.
The CFSAC structure has been
expanded to include three non-voting
liaison representative positions.
Authorization was given for the
Committee structure to include the three
non-voting liaison representative
positions when the charter was renewed
on September 5, 2012. These positions
will be occupied by individuals who are
selected by their organizations to serve
as the official representative for
organizations that are concerned with
ME/CFS. Organizations will occupy
these representative positions for a twoyear term.
Nominations
The OASH is requesting nominations
of organizations to fill three non-voting
liaison representative positions for the
CFSAC. The represented organizations
will be selected by the DFO or designee
during the 2013 calendar year.
Selection of organizations that will
serve as non-voting liaison
representatives will be based on the
organization’s qualifications to
contribute to the accomplishment of the
CFSAC mission, as described in the
Committee charter. In selecting
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
5455
organizations to be considered for these
positions, the OASH will give close
attention to equitable geographic
distribution and give priority to U.S.chartered 501(c)(3) organizations that
operate within the United States and
have membership with demonstrated
expertise in ME/CFS and related
research, clinical services, or advocacy
and outreach on issues concerning ME/
CFS.
The individual designated to serve as
the official non-voting liaison
representative will perform the
associated duties without
compensation, and will not receive per
diem or reimbursement for travel
expenses. The organizations that are
selected to be represented will cover
expenses for the designated
representative to attend, at a minimum,
one in-person CFSAC meeting per year
during the designated term of
appointment.
To qualify for consideration of
selection to the Committee, an
organization should submit the
following items:
(1) A statement of the organization’s
history, mission, and focus, including
information that demonstrates the
organization’s experience and expertise
in ME/CFS and related research, clinical
services, or advocacy and outreach on
issues of ME/CFS, as well as expert
knowledge of the broad issues and
topics pertinent to ME/CFS. This
information should demonstrate the
organization’s proven ability to work
and communicate with the ME/CFS
patient and advocacy community, and
other public/private organizations
concerned with ME/CFS, including
public health agencies at the federal,
state, and local levels.
(2) One to three letters of
recommendation that clearly state why
the organization is qualified to serve on
CFSAC in a representative position.
These letters should be from individuals
who are not part of the organization’s
leadership.
(3) A statement that the organization
is willing to serve as a non-voting
liaison representative of the Committee
and will cover expenses for an
individual representative to attend inperson, at a minimum, one CFSAC
meeting per year in Washington, DC
during the designated term of
appointment.
(4) A current financial disclosure
statement (or annual report)
demonstrating the organization’s ability
to cover expenses for an individual to
attend, at a minimum, one CFSAC
meeting per year in Washington, DC,
during the term of appointment.
E:\FR\FM\25JAN1.SGM
25JAN1
5456
Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices
Submitted nominations must include
these critical elements in order for the
organization to be considered for one of
the non-voting liaison representative
positions.
Nomination materials should be
typewritten, 12-point type and doublespaced. All nomination materials
should be submitted (postmarked or
received) by February 22, 2013.
Electronic submissions: Nomination
materials, including attachments, may
be submitted electronically to
cfsac@hhs.gov.
Telephone and facsimile submissions
cannot be accepted.
Regular, Express, or Overnight Mail:
Written documents may be submitted to
the following addressee only: Nancy C.
Lee, Designated Federal Officer, CFSAC,
Office on Women’s Health, Department
of Health and Human Services, 200
Independence Ave. SW., Room 712E,
Washington, DC 20201.
HHS makes every effort to ensure that
the membership of Federal advisory
committees is fairly balanced in terms of
points of view represented. Every effort
is made to ensure that a broad
representation of geographic areas, sex,
ethnic and minority groups, and people
with disabilities are given consideration
for membership on Federal advisory
committees. Selection of the represented
organizations shall be made without
discrimination against the composition
of an organization’s membership on the
basis of age, sex, race, ethnicity, sexual
orientation, disability, and cultural,
religious, or socioeconomic status.
Dated: January 18, 2013.
Nancy C. Lee,
Designated Federal Officer, Chronic Fatigue
Syndrome Advisory Committee.
[FR Doc. 2013–01456 Filed 1–24–13; 8:45 am]
BILLING CODE 4150–42–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day-13–0841]
mstockstill on DSK4VPTVN1PROD with
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–7570 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
VerDate Mar<15>2010
18:39 Jan 24, 2013
Jkt 229001
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Management Information System for
Comprehensive Cancer Control
Programs—Revision (OMB No. 0920–
0841, exp. 1/31/2013)—National Center
for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
Through the National Comprehensive
Cancer Control Program (NCCCP), CDC
currently provides cooperative
agreement funding and technical
assistance to 65 entities: all 50 states,
the District of Columbia, seven tribes/
tribal organizations, and seven
territories/U.S. Pacific Island
jurisdictions. Since January 2010,
NCCCP awardees have submitted
progress and activity information to
CDC twice per year using an electronic
information system (‘‘Management
Information System for Comprehensive
Cancer Control Programs,’’ OMB No.
0920–0841, exp. 1/31/2013). The
program director for each awardee is
responsible for overseeing activities and
submitting the required reports to CDC.
New cooperative agreements were
awarded to all NCCCP programs in 2012
(‘‘Cancer Prevention and Control
Program for State, Territorial and Tribal
Organizations,’’ Funding Opportunity
Announcement (FOA) DP12–1205). The
new cooperative agreements place
increased emphasis on policy and
environmental approaches to cancer
prevention and control.
CDC seeks OMB approval to continue
using MIS-based reporting for the
NCCCP awardees. Minor changes to the
existing core cancer prevention and
control data elements will be
implemented to reflect the FOA’s new
performance requirements.
Thirteen of the 65 NCCCP awardees
received additional funding for related
but distinct cooperative agreements
(‘‘Demonstrating the Capacity of
Comprehensive Cancer Control
Programs to Implement Policy and
Environmental Cancer Control
Interventions,’’ FOA DP10–1017). The
demonstration program is aimed at
accelerating the development of policy
and environmental approaches to cancer
control for awardees that are poised to
move forward rapidly. Demonstration
program activities will be aligned with
the existing comprehensive cancer
control program in a manner that
minimizes duplication, capitalizes on
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
existing activities, and fosters rapid
implementation. Similar semi-annual
progress reports are required to monitor
activities conducted under the
demonstration program. A state- or
territory-based policy task force
coordinator will be responsible for
submitting the required reports to CDC.
CDC proposes to use the same MISbased methodology for all reporting.
Due to the distinct objectives, resources,
and activities associated with each
cooperative agreement, separate reports
will be required from the program
director and the task force coordinator.
CDC’s Revision request utilizes a
modified method of estimating
respondent burden which distinguishes
between (i) the initial burden of
populating the MIS, and (ii) routine MIS
maintenance and report generation. In
the initial OMB approval period (2010–
2013), respondent burden was based on
a long-term average burden per
response.
For the 65 state- and territory-based
cancer prevention and control programs,
CDC estimates the initial burden of
populating the MIS at four hours per
response. Some of the information
entered into the MIS during the
previous cooperative agreement period
will be downloaded to minimize
respondent burden in the new funding
period, but awardees will be responsible
for verifying this information and
entering new objectives. After
completing these steps, the estimated
burden for ongoing system maintenance
and semi-annual reporting is three
hours per response.
For the 13 states and territories that
are also participating in the
demonstration program, the initial
burden of populating the MIS is
estimated to be six hours per response.
Awardees will be responsible for
entering information about the new
objectives, staff, and other resources for
demonstration program activities.
Thereafter, the estimated burden for
ongoing system maintenance and semiannual reporting is estimated at three
hours per response.
OMB approval is requested for three
years. Information will be reported
electronically twice per year. CDC will
use the reports to identify training and
technical assistance needs, monitor
compliance with cooperative agreement
requirements, evaluate progress made in
achieving program-specific goals, and
obtain information needed to respond to
inquiries. There are no costs to
respondents other than their time. The
total estimated annualized burden hours
are 586.
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 78, Number 17 (Friday, January 25, 2013)]
[Notices]
[Pages 5454-5456]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01456]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Solicitation of Nominations for Organizations To Serve as Non-
Voting Liaison Representatives to the Chronic Fatigue Syndrome Advisory
Committee (CFSAC)
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
Authority: 42 U.S.C. 217a, section 222 of the Public Health
Service (PHS) Act, as amended. The committee is governed by the
provisions of the Federal Advisory Committee Act, as amended (5
U.S.C. App 2), which sets forth standards for the formation and use
of advisory committees.
SUMMARY: The Office of the Assistant Secretary for Health (OASH),
within the Department of Health and Human Services (HHS), is soliciting
nominations from qualified organizations to be considered for non-
voting liaison representative positions
[[Page 5455]]
on the Chronic Fatigue Syndrome Advisory Committee (CFSAC). CFSAC
provides advice and recommendations to the Secretary of HHS, through
the Assistant Secretary for Health (ASH), on a broad range of issues
and topics related to myalgic encephalomyelitis/chronic fatigue
syndrome (ME/CFS). The issues can include factors affecting access and
care for persons with ME/CFS; the science and definition of ME/CFS; and
public health, clinical, research, and educational issues related to
ME/CFS. These three non-voting liaison representative positions will be
occupied by individuals who are selected by their organizations to
serve as representatives of organizations concerned with ME/CFS.
Organizations will be designated to occupy the positions for a two-year
term to commence during the 2013 calendar year. Nominations of
qualified organizations are being sought for these three non-voting
liaison representative positions. The organizations chosen for
representation on CFSAC will be selected by the Designated Federal
Officer (DFO) or designee during the 2013 calendar year. Details of
nomination requirements are provided below.
DATES: Nominations must be received no later than 5 p.m. EDT on
February 22, 2013, at the address listed below.
ADDRESSES: All nominations should be mailed or delivered to Nancy C.
Lee, M.D., Designated Federal Officer, Chronic Fatigue Syndrome
Advisory Committee, Office on Women's Health, Department of Health and
Human Services, 200 Independence Ave. SW., Room 712E, Washington, DC
20201. Nomination materials, including attachments, may be submitted
electronically to cfsac@hhs.gov.
FOR FURTHER INFORMATION CONTACT: Nancy C. Lee, M.D., Designated Federal
Officer, Chronic Fatigue Syndrome Advisory Committee, Office on Women's
Health, Department of Health and Human Services, 200 Independence Ave.
SW., Room 712E, Washington, DC 20201. Inquiries can be sent to
cfsac@hhs.gov.
SUPPLEMENTARY INFORMATION: CFSAC was established on September 5, 2002.
The purpose of the CFSAC is to provide advice and recommendations to
the Secretary of HHS, through the ASH, on issues related to ME/CFS.
CFSAC advises and makes recommendations on a broad range of topics
including: (1) The current state of knowledge and research; the
relevant gaps in knowledge and research about the epidemiology,
etiologies, biomarkers and risk factors relating to ME/CFS; and
potential opportunities in these areas; (2) impact and implications of
current and proposed diagnostic and treatment methods for ME/CFS; (3)
development and implementation of programs to inform the public, health
care professionals, and the biomedical research communities about ME/
CFS advances; and (4) strategies to improve the quality of life of ME/
CFS patients. Management and support services for Committee activities
are provided by staff from the HHS Office on Women's Health, within the
OASH. The CFSAC charter is available at https://www.hhs.gov/advcomcfs/charter/.
CFSAC meetings are held not less than two times per year. The CFSAC
membership consists of 11 voting members, including the Chair. The
voting members are composed of seven biomedical research scientists,
and four individuals with expertise in health insurance, health care
delivery, private health care services, or representatives of voluntary
organizations concerned with the problems of individuals with ME/CFS.
CFSAC also includes seven non-voting ex officio member representatives
from the Agency for Healthcare Research and Quality, Centers for
Disease Control and Prevention, Centers for Medicare and Medicaid
Services, Food and Drug Administration, Health Resources and Services
Administration, National Institutes of Health, and Social Security
Administration.
The CFSAC structure has been expanded to include three non-voting
liaison representative positions. Authorization was given for the
Committee structure to include the three non-voting liaison
representative positions when the charter was renewed on September 5,
2012. These positions will be occupied by individuals who are selected
by their organizations to serve as the official representative for
organizations that are concerned with ME/CFS. Organizations will occupy
these representative positions for a two-year term.
Nominations
The OASH is requesting nominations of organizations to fill three
non-voting liaison representative positions for the CFSAC. The
represented organizations will be selected by the DFO or designee
during the 2013 calendar year.
Selection of organizations that will serve as non-voting liaison
representatives will be based on the organization's qualifications to
contribute to the accomplishment of the CFSAC mission, as described in
the Committee charter. In selecting organizations to be considered for
these positions, the OASH will give close attention to equitable
geographic distribution and give priority to U.S.-chartered 501(c)(3)
organizations that operate within the United States and have membership
with demonstrated expertise in ME/CFS and related research, clinical
services, or advocacy and outreach on issues concerning ME/CFS.
The individual designated to serve as the official non-voting
liaison representative will perform the associated duties without
compensation, and will not receive per diem or reimbursement for travel
expenses. The organizations that are selected to be represented will
cover expenses for the designated representative to attend, at a
minimum, one in-person CFSAC meeting per year during the designated
term of appointment.
To qualify for consideration of selection to the Committee, an
organization should submit the following items:
(1) A statement of the organization's history, mission, and focus,
including information that demonstrates the organization's experience
and expertise in ME/CFS and related research, clinical services, or
advocacy and outreach on issues of ME/CFS, as well as expert knowledge
of the broad issues and topics pertinent to ME/CFS. This information
should demonstrate the organization's proven ability to work and
communicate with the ME/CFS patient and advocacy community, and other
public/private organizations concerned with ME/CFS, including public
health agencies at the federal, state, and local levels.
(2) One to three letters of recommendation that clearly state why
the organization is qualified to serve on CFSAC in a representative
position. These letters should be from individuals who are not part of
the organization's leadership.
(3) A statement that the organization is willing to serve as a non-
voting liaison representative of the Committee and will cover expenses
for an individual representative to attend in-person, at a minimum, one
CFSAC meeting per year in Washington, DC during the designated term of
appointment.
(4) A current financial disclosure statement (or annual report)
demonstrating the organization's ability to cover expenses for an
individual to attend, at a minimum, one CFSAC meeting per year in
Washington, DC, during the term of appointment.
[[Page 5456]]
Submitted nominations must include these critical elements in order
for the organization to be considered for one of the non-voting liaison
representative positions.
Nomination materials should be typewritten, 12-point type and
double-spaced. All nomination materials should be submitted (postmarked
or received) by February 22, 2013.
Electronic submissions: Nomination materials, including
attachments, may be submitted electronically to cfsac@hhs.gov.
Telephone and facsimile submissions cannot be accepted.
Regular, Express, or Overnight Mail: Written documents may be
submitted to the following addressee only: Nancy C. Lee, Designated
Federal Officer, CFSAC, Office on Women's Health, Department of Health
and Human Services, 200 Independence Ave. SW., Room 712E, Washington,
DC 20201.
HHS makes every effort to ensure that the membership of Federal
advisory committees is fairly balanced in terms of points of view
represented. Every effort is made to ensure that a broad representation
of geographic areas, sex, ethnic and minority groups, and people with
disabilities are given consideration for membership on Federal advisory
committees. Selection of the represented organizations shall be made
without discrimination against the composition of an organization's
membership on the basis of age, sex, race, ethnicity, sexual
orientation, disability, and cultural, religious, or socioeconomic
status.
Dated: January 18, 2013.
Nancy C. Lee,
Designated Federal Officer, Chronic Fatigue Syndrome Advisory
Committee.
[FR Doc. 2013-01456 Filed 1-24-13; 8:45 am]
BILLING CODE 4150-42-P
